United States
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 10-QSB


             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                For the Quarterly Period Ended: February 29, 2008

                         Commission File Number: 0-11050


                              MAMMATECH CORPORATION
                              ---------------------
               (Exact name of registrant as specified in charter)


           Florida                                         59-2181303
           -------                                         ----------
(State or other jurisdiction of                (IRS Employer Identification No.)
incorporation or organization)


                 930 N.W. 8th Avenue, Gainesville, Florida 32601
                 -----------------------------------------------
              (Address of principal executive offices and zip code)


                                 (352) 375-0607
                                 --------------
              (Registrant's telephone number, including area code)

                                       N/A
                                       ---
          (Former Name or Former Address, if Changed Since Last Report)

Check whether the Issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the Registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ] .

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X] .

As of April 2, 2008, there were 5,123,700 shares of common stock, par value
$0.0001 per share, outstanding.

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

<PAGE>

TABLE OF CONTENTS

PART I.    FINANCIAL INFORMATION

       Item 1.    Financial Statements


           Balance Sheet as of February 29, 2008 (unaudited)                 1


           Statements of Operations for the three and six month periods
           ended February 29, 2008 and February 28, 2007 (unaudited)         2


           Statements of Cash Flows for the six month periods
           ended February 29, 2008 and February 28, 2007 (unaudited)         3


           Notes to Financial Statements (unaudited)                         4


       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations              5


       Item 3.    Controls and Procedures                                    8


PART II.   OTHER INFORMATION

       Item 1.    Legal Proceedings                                          9
       Item 2.    Changes in Securities and Use of Proceeds                  9
       Item 3.    Defaults upon Senior Securities                            9
       Item 4.    Submission of Matters to a Vote of Security Holders        9
       Item 5.    Other information                                          9
       Item 6.    Exhibits and Reports on Form 8-K                           9

           Signatures                                                       10

           Certifications
                  Exhibits 31.1 and 31.2                                   11-12
                  Exhibits 32.1 and 32.2                                   13-14

<PAGE>

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS






<PAGE>

                              Mammatech Corporation
                                  Balance Sheet
                                February 29, 2008
                                   (unaudited)
ASSETS
Current assets:
  Cash                                                              $   323,804
  Accounts receivable - trade                                            16,551
  Inventory                                                              83,375
                                                                    -----------
      Total current assets                                              423,730
                                                                    -----------

Property and equipment, at cost, net of accumulated
  depreciation of $288,824                                              262,290
                                                                    -----------

Available for sale securities                                           207,700
Other assets                                                              4,653
                                                                    -----------
                                                                        212,353
                                                                    -----------
TOTAL ASSETS                                                        $   898,373
                                                                    ===========

LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current liabilities:
  Accounts payable and accrued expenses                             $    26,689
  Accounts payable and accrued salaries - officers                    1,095,789
                                                                    -----------
      Total current liabilities                                       1,122,478
                                                                    -----------

Stockholders' (deficit):
 Common stock, $.0001 par value,
  200,000,000 shares authorized, 5,427,625 issued
  and 5,123,700 outstanding                                                 543
 Additional paid-in capital                                           2,896,186
 Accumulated (deficit)                                               (2,952,187)
                                                                    -----------
                                                                        (55,458)
 Treasury stock, at cost, 303,925 shares                               (148,051)
                                                                    -----------
                                                                       (203,509)
Other comprehensive income:
 Unrealized gain (loss) on marketable securities                        (20,596)
                                                                    -----------
                                                                       (224,105)
                                                                    -----------
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)                       $   898,373
                                                                    ===========


   The accompanying notes are an integral part of these financial statements.

                                        1
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>


                                          Mammatech Corporation
                                 Statements of Comprehensive Operations
                Three Months and Six Months Ended February 28, 2007 and February 29, 2008
                                               (unaudited)


                                                        Three Months                  Six Months
                                                 --------------------------    --------------------------
                                                     2007           2008           2007           2008
                                                 -----------    -----------    -----------    -----------

Sales, net                                       $    76,647    $    93,787    $   181,955    $   178,267
Cost of sales                                         12,864          7,345         40,532         30,436
                                                 -----------    -----------    -----------    -----------
Gross profit                                          63,783         86,442        141,423        147,831
                                                 -----------    -----------    -----------    -----------

Selling, general and administrative expenses          81,946         98,283        193,307        221,691
                                                 -----------    -----------    -----------    -----------
(Loss) from operations                               (18,163)       (11,841)       (51,884)       (73,860)
                                                 -----------    -----------    -----------    -----------

Other income and (expense):
  Gain (loss) on sale of investment securities          --             --           (4,228)          (279)
  Interest and dividend income                         7,443          8,013         11,831         16,080
                                                 -----------    -----------    -----------    -----------
                                                       7,443          8,013          7,603         15,801
                                                 -----------    -----------    -----------    -----------

(Loss) before income taxes                           (10,720)        (3,828)       (44,281)       (58,059)
Provision for income taxes                              --             --             --             --
                                                 -----------    -----------    -----------    -----------
Net (loss)                                       $   (10,720)   $    (3,828)   $   (44,281)   $   (58,059)
                                                 ===========    ===========    ===========    ===========

Basic and fully diluted earnings per share:
 Net (loss)                                      $     (0.00)   $     (0.00)   $     (0.01)   $     (0.01)
                                                 ===========    ===========    ===========    ===========
 Weighted average shares                           5,427,625      5,427,625      5,427,625      5,427,625
                                                 ===========    ===========    ===========    ===========

  Net (loss)                                     $   (10,720)   $    (3,828)   $   (44,281)   $   (58,059)
   Unrealized gain (loss) from investments,
    net of income taxes                                4,000        (10,580)        27,354        (15,581)
                                                 -----------    -----------    -----------    -----------
  Comprehensive (loss)                           $    (6,720)   $   (14,408)   $   (16,927)   $   (73,640)
                                                 ===========    ===========    ===========    ===========


               The accompanying notes are an integral part of these financial statements.

                                                    2
<PAGE>

                               Mammatech Corporation
                             Statements of Cash Flows
             Six Months Ended February 28, 2007 and February 29, 2008
                                    (unaudited)

                                                                2007         2008
                                                             ---------    ---------
Cash flows from operating activities:
  Net cash provided by (used in) operating activities        $  24,063    $   3,630
                                                             ---------    ---------

Cash flows from investing activities:
   Purchase of available for sale securities                   (85,275)     (15,820)
   Proceeds from the sale of available for sale securities     116,005       10,190
   Net sales (purchases) of fixed assets                         7,546       (2,085)
                                                             ---------    ---------
Net cash provided by (used in) investing activities             38,276       (7,715)
                                                             ---------    ---------

Cash flows from financing activities:
Payment of notes payable                                        (5,200)        --
                                                             ---------    ---------
Net cash provided by (used in) financing activities             (5,200)        --
                                                             ---------    ---------

Increase (decrease) in cash                                     57,139       (4,085)

Cash and cash equivalents,
 beginning of period                                            23,707      327,889
                                                             ---------    ---------
Cash and cash equivalents,
 end of period                                               $  80,846    $ 323,804
                                                             =========    =========



    The accompanying notes are an integral part of these financial statements.

                                         3
</TABLE>
<PAGE>

                              MAMMATECH CORPORATION
                          NOTES TO FINANCIAL STATEMENTS
                                FEBRUARY 29, 2008
                                   (UNAUDITED)

(1)      Basis Of Presentation
The accompanying unaudited financial statements have been prepared in accordance
with generally accepted accounting principles (GAAP) for interim financial
information and Item 310(b) of Regulation S-B. They do not include all of the
information and footnotes required by GAAP for complete financial statements. In
the opinion of management, all adjustments (consisting only of normal recurring
adjustments) considered necessary for a fair presentation have been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year. For further
information, refer to the financial statements of the Company as of August 31,
2007, and for the two years then ended, including notes thereto included in the
Company's Form 10-KSB.

(2)      Earnings Per Share
The Company calculates net income (loss) per share as required by Statement of
Financial Accounting Standards (SFAS) 128, "Earnings per Share." Basic earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares outstanding for the period. Diluted earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares and dilutive common stock equivalents
outstanding. During periods when anti-dilutive commons stock equivalents are not
considered in the computation.

(3)      Inventory
Inventory is stated at the lower of cost, determined on a first in, first out
basis, or market value. Inventory consists principally of finished goods and
packaging materials.

(4)      Available For Sale Securities
Marketable securities consist of the following at February 29, 2008: Mutual
funds and equity securities with a fair market value of $207,700. The cost basis
of these securities is $228,296.

The gross realized losses on sales of available-for-sale securities were $279
during the six months ended February 29, 2008. The unrealized holding losses on
available-for-sale securities included in accumulated other comprehensive income
as a component of stockholders' equity increased by $15,581 during the six
months ended February 29, 2008, and totaled $20,596 at February 29, 2008. During
the six months ended February 29, 2008, the Company realized net proceeds from
the sale of available for sale securities of $10,190 and purchased securities
available for sale at a cost of $15,820.

(5)      Grants
The Company was awarded a Phase I SBIR Grant from the National Cancer Institute
in 2006. The specific objective of the Phase I grant is to evaluate the
capability of a novel prototype online learning system to teach quality-standard
Clinical Breast Examination (CBE) to medical professionals. The Company refers
to this as the Palpation Assessment Device (PAD), a computer-based system that
teaches and evaluates manual breast examination skills. The original amount of
the research grant was approximately $158,400. During the year ended August 31,
2007, the Company received $93,000 in funding under the grant, and during the
six months ended February 29, 2008, the Company received $30,510 in funding
under the grant. The grant funds are used for equipment, consultants and staff
to develop the PAD technology. The Company accounts for funds received under
this grant for cost reimbursement as a reduction in general and administrative
expenses.

                                        4
<PAGE>

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
          CONDITION AND RESULTS OF OPERATIONS


Forward-Looking Statements

The following discussion should be read in conjunction with the accompanying
financial statements and notes thereto included within this Quarterly Report on
Form 10-QSB. In addition to historical information, the information in this
discussion contains forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. These forward-looking statements involve risks
and uncertainties, including statements regarding the Company's capital needs,
business strategy and expectations. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such
as "may", "will", "should", "expect", "plan", "Intend", "anticipate", "believe",
estimate", "predict", "potential" or "continue", the negative of such terms or
other comparable terminology. Actual events or results may differ materially. In
evaluating these statements, you should consider various factors described in
this Quarterly Report, including the risk factors accompanying this Quarterly
Report, and, from time to time, in other reports the Company files with the
Securities and Exchange Commission. These factors may cause the Company's actual
results to differ materially from any forward-looking statement. The Company
disclaims any obligation to publicly update these statements, or disclose any
difference between its actual results and those reflected in these statements.
The information constitutes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.

Company Background

The Company is engaged in the sale of a patented breast tumor detection training
system (the "MammaCare System"). Using life-like models of a human female
breast, the MammaCare System is designed to train individuals to perform
effective manual breast examination. The breast models contain simulated tumors
of varying sizes, ranging from under 5mm. to over 10mm. They also contain
material which simulates the normal nodularity, or "lumpiness," that
characterizes most breast tissue.

Although the examiner can never determine by feel alone whether a lump is benign
or malignant, detection of tumors in the size range simulated by the models is
important to early diagnosis of malignancies. Thus, the Company believes that by
training women to palpate the breast model (and their own breasts) properly, the
MammaCare System will lead to early detection of breast cancer and thus reduce
morbidity and mortality due to this disease.

The MammaCare System is sold in several forms, all of which contain at least one
of the Company's patented breast models. Originally, a client was given private
training after which she was provided with a take-home breast model and other
materials. Now, the customer may view a video tape developed by the Company
which teaches her the proper use of the model(s) and an extremely thorough
examination technique. The practice model is designed to permit a woman to
reinforce her lump detection skills periodically and serves as a comparative
standard as she palpates her own breast.

The Company's primary marketing strategy is designed to encourage sales through
physicians, hospitals and diagnostic centers. Under this marketing approach,
health care providers purchase the MammaCare Professional Learning System
directly from the Company. The Company does not generate any revenues from the
use of the Learning System by women, and the Company's sole revenues come from
sales of MammaCare System and any accompanying training.

The MammaCare Professional Learning System consists of a teaching model, a
24-minute video cassette, and practice kit. The teaching model is a patented
breast model, designed to teach the difference between the feel of normal,

                                        5
<PAGE>

nodular breast tissue and the feel of small lesions. The video cassette guides
the learner through a series step-by-step exercises, first on the models, then
on her own breast tissue. This is intended to lead to mastery level proficiency
in palpation, search technique and lump detection. The practice kit contains a
"take-home" breast model, a written review manual, a reminder calendar and a
record booklet.

A patient may purchase the practice kit portion of the MammaCare System for
continued monthly reinforcement of her skills. Patients may view the videotape
either in their homes or in the provider's facility. In either case, a patient
should have her proficiency reviewed by a physician or certified MammaCare
Specialist.

By obtaining the MammaCare System from their own providers, patients are assured
of receiving the full quality of MammaCare without the inconvenience and expense
of a lengthy clinic visit. Further, it is anticipated that the cost of MammaCare
to the public will be lower than historical prices charged for clinical
services. However, while the Company has made providers aware of the need to
keep the price of MammaCare reasonable, the providers are free to charge
whatever fee they deem appropriate for the use of the MammaCare System. In light
of the fact that most health insurance policies do not reimburse patients for
any portion of their MammaCare expenses, no assurance can be given that the
physicians will set prices low enough to attract patients.

To date, there are over 1,000 physicians, hospitals and diagnostic centers
throughout the United States providing the Learning System to women. No
assurances can be given that the Company's marketing approach will be
successful. For the Company to achieve profitability, MammaCare must be provided
to an ever increasing number of women.

Recent Developments

During the year ended August 31, 2007, the Company trained and certified 19
MammaCare Specialists, 41 MammaCare Clinical Breast Examiners and 136 MammaCare
Breast Self Exam (BSE) Instructors. During the six months ended February 29,
2008, the Company trained and certified no MammaCare Specialists, 7 MammaCare
Clinical Breast Examiners and 28 MammaCare Breast Self Exam (BSE) Instructors.
These new certifications were primarily related to the Company's German
affiliate and the Company's new relationship with Alexian Brothers Hospital
Network, discussed below.

The Company is continuing to pursue its strategy of establishing additional
training sites both in the United States and abroad. The Company concluded
negotiations with Alexian Brothers Hospital Network in Elk Grove Village, IL,
and a MammaCare Training Center was opened in that location in December 2006.
There can be no assurance, however, that significant revenues will result from
this operation.

The Company continues to expend resources to complete development of its
patented tactile computer technology tentatively termed the Palpation Assessment
Device (PAD). The PAD is the first computer-based system that teaches and
evaluates manual breast examination skills. During the year ended August 31,
2006, the Company received a Phase I SBIR grant from the National Cancer
Institute to complete development of the PAD and to evaluate its utility in an
online learning environment. Currently, the PAD continues to undergo testing as
part of MammaCare Specialist training.

The Company continues to seek a larger partner in the healthcare industry to
increase the distribution of its products.


                                        6
<PAGE>

Results of Operations

Comparison of Three Months Ended February 29, 2008 and February 28, 2007
------------------------------------------------------------------------

The Company's net sales were $93,787 for the three months ended February 29,
2008 compared to $76,647 during the three months ended February 28, 2007, an
increase of approximately 22% from the prior period. Gross profit was $86,442
for the three months ended February 29, 2008 compared to $63,783 for the three
months ended February 28, 2007, an increase of approximately 35% from the prior
period. Gross profit margin for the three months ended February 29, 2008 and
February 28, 2007 was 92% and 83%, respectively.

Selling, general and administrative expenses increased from $81,946 for the
three months ended February 28, 2007 to $98,283 for the three months ended
February 29, 2008. During the three months ended February 28, 2008, grant
funding totaling approximately $25,500 was recorded as a reduction of selling,
general and administrative expenses. Loss from operations for the three months
ended February 29, 2008 and February 28, 2007 was ($11,841) and ($18,163),
respectively, a decrease of approximately 34% from the prior period.

The Company had net loss of ($10,720) for the three months ended February 28,
2007 and net loss of ($3,828) for the three months ended February 29, 2008. This
change was primarily related to an increase in net sales and gross profit which
was partially offset by an increase in selling, general and administrative
expenses in the current period.

Comparison of Six Months Ended February 29, 2008 and February 28, 2007
----------------------------------------------------------------------

The Company's net sales were $178,267 for the six months ended February 29, 2008
compared to $181,955 during the six months ended February 28, 2007, a decrease
of approximately 2% from the prior period. Gross profit was $147,831 for the six
months ended February 29, 2008 compared to $141,423 for the six months ended
February 28, 2007, an increase of approximately 5% from the prior period. Gross
profit margin for the six months ended February 29, 2008 and February 28, 2007
was 83% and 78%, respectively.

Selling, general and administrative expenses increased from $193,307 for the six
months ended February 28, 2007 to $221,691 for the six months ended February 29,
2008. During the six months ended February 28, 2008, grant funding totaling
approximately $30,500 was recorded as a reduction of selling, general and
administrative expenses. Loss from operations for the six months ended February
29, 2008 and February 28, 2007 was ($73,860) and ($51,884), respectively, an
increase of approximately 42% from the prior period.

The Company had net loss of ($44,281) for the six months ended February 28, 2007
and net loss of ($58,059) for the six months ended February 29, 2008. This
change was primarily related to an increase in selling, general and
administrative expenses in the current period.


                                        7
<PAGE>

Liquidity and Capital Resources

The Company has no immediate liquidity problems. At February 29, 2008, the
Company had cash on hand of $323,804 and marketable securities of $207,700.
During the six months ended February 29, 2008, the Company realized net proceeds
from the sale of available for sale securities of $10,190. At February 29, 2008,
the Company has accounts payable and accrued salaries owing to its officers of
$1,095,789.

The Company intends to use its capital resources to fund its product development
and to expand distribution. The Company believes these capital resources are
sufficient to allow the Company to attract potential interest from a strategic
partner and to make it an attractive candidate for grant funding from public and
private sources. However, there can be no assurance these capital resources will
be sufficient to allow the Company to implement its marketing strategies or to
become profitable.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

ITEM 3.  CONTROLS AND PROCEDURES

As of the end of the period covered by this Report, the Company's Chief
Executive Officer and Chief Financial Officer evaluated the effectiveness of the
Company's disclosure controls and procedures. Based on the evaluation, the
Company's Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures are effective as of the end of the
period covered by this Report in that information required to be disclosed in
reports filed under the Securities Exchange Act of 1934, as amended, has been
recorded, processed, summarized and reported within the current fiscal quarter.
There were no changes in the Company's internal control over financial reporting
that occurred during the Company's most recent fiscal quarter that have
materially affected, or are reasonably likely to materially affect, the
Company's internal control over financial reporting.





                                        8
<PAGE>

PART II. OTHER INFORMATION

Item 1.  Legal Proceedings

         None

Item 2.  Changes in Securities

         None

Item 3.  Defaults Upon Senior Securities

         None

Item 4.  Submission of Matters to a Vote of Security Holders

         None

Item 5.  Other Information

         None

Item 6.  Exhibits and Reports on Form 8-K

         (a)   Exhibits

         31.1  Certification of Chief Executive Officer pursuant to Section
               302 of the Sarbanes-Oxley Act of 2002 (as filed herewith).

         31.2  Certification of Chief Financial Officer pursuant to Section
               302 of the Sarbanes-Oxley Act of 2002 (as filed herewith).

         32.1  Certification of Chief Executive Officer pursuant to Section
               906 of the Sarbanes-Oxley Act of 2002 (as filed herewith).

         32.2  Certification of Chief Financial Officer pursuant to Section
               906 of the Sarbanes-Oxley Act of 2002 (as filed herewith).


         (b)   Reports on Form 8-K

               None



                                        9
<PAGE>


                                   Signatures



In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                             MAMMATECH CORPORATION



Date:   April 9, 2008                        By: /s/ Henry S. Pennypacker
                                                 -------------------------
                                                 Henry S. Pennypacker, CEO



Date:   April 9, 2008                        By: /s/ Mary Sellers
                                                 -------------------------
                                                 Mary Sellers, CFO and Treasurer






                                       10